SecBot SecBot
SECBOTREPLAY Home › Report › ATRA

ATRA · Atara Biotherapeutics disclosed the departure of Chief Accounting…

Atara Biotherapeutics, Inc. · 8-K filed Jun 26, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 26, 2026 at 16:15 ET

Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO via a consulting agreement with Charles River CFO, Inc. The filing is a routine officer change and carries no material financial information.

  • Chief Accounting Officer Yanina Grant-Huerta notified of employment end effective July 17, 2026.
  • Kevin G. Sarney appointed interim CFO, principal financial officer, and principal accounting officer on June 26, 2026.
  • Sarney, age 61, is a CPA with 25+ years of life science finance experience, serving via a consulting agreement with Charles River CFO, Inc. at an hourly rate.
  • No compensation directly to Sarney; consulting agreement can be terminated with 30 days' notice.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access